-
Metastatic Non-Small Cell Lung Cancer: Highlights from WCLC and ESMO 2024
This year, the first three weeks of September were packed with lung cancer research updates at the World Conference on Lung Cancer (WCLC) from September 7-10 in San Diego followed by the European...
IN THE SPOTLIGHT
-
Eating Healthy on the Mediterranean Diet
Read time: 3 minutes. Oncology dietitian Lori Bumbaco takes us on a culinary journey, exploring why experts consistently rank the Mediterranean diet as the number one choice for... -
How Do Drugs Get Approved (and Fast-Tracked) by the FDA?
Read time: 5 minutes. This is Part 3 in our series on how drugs get approved to treat lung cancer. Part 1: Understanding Clinical Trials - Why Are They Important for Drug... -
How We Define Success for a Clinical Trial
Read time: 6 minutes. This is Part 2 of 3 in our series on how drugs get approved to treat lung cancer. Make sure to read Part 1 on the phases of clinical trials and why they are... -
Understanding Clinical Trials: Why Are They Important for Drug Development?
Read time: 3 minutes. This is Part 1 in a 3-part series explaining how new drugs and treatments get approved to treat lung cancer. Parts 2 and 3 will be published in the coming... -
HER2+ NSCLC: Understanding the Latest Treatment and Advances
Many people have heard of HER2-positive breast cancer. But HER2 is an important biomarker found in many different types of cancer—including non-small cell lung cancer (NSCLC). A... -
How Can Patients and Researchers Design Clinical Trials Together?
Read time: 2 minutes. Traditionally, people associate getting involved in lung cancer research with enrolling in a clinical trial. But most don’t realize they can also partner with... -
Rare Mutations (RET, ROS1, MET, BRAF) Virtual Meetup
Rare Mutation (RET, ROS1, MET, BRAF) patients/survivors - Join us the 1st Wednesday of every month to c onnect with others who share common experiences and build your community... -
2024 ASCO: Highlights of Lung Cancer Research
Read time: 8 minutes Thousands of oncologists, scientists, biotech and pharmaceutical representatives, patients, and advocates (including LUNGevity staff) met to discuss lifesaving...
Let Your Voice Be Heard!
Let Your Voice Be Heard!
We are collecting stories from patients, caregivers, friends, and family members! Tell us how lung cancer has affected your life. Email your story to us at support@lungevity.org. Thanks!
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
RET, MET, and EGFR: An unusual tale of three oncogenes in lung cancer
LUNGevity's Upal Basu Roy, PhD, MPH, Executive Director, Research, discusses innovative research into RET+ NSCLC with patient advocates and the scientist conducting the studies. Panelists include Omaima Salous (diagnosed with RET+ NSCLC and co-founder of The Hamoui Foundation), Dr. Hilary Hammell (diagnosed with RET+ NSCLC and co-chair of RETpositive), and Dr. Tejas Patil (Assistant Professor, University of Colorado). The discussion focuses on Dr. Patil’s RET+ NSCLC research project…